Please login to the form below

Not currently logged in

Haemophilia Society launches UK awareness drive

Charity tackles poor understanding of bleeding disorder
Talking Red

The Haemophilia Society is making a bid to tackle poor understanding of bleeding disorders and raise awareness of the tens of thousands of women who may suffering from a bleeding disorder without realising it.

The UK charity is encouraging everyone to get 'Talking Red' during its first awareness week, launched on June 14 and supported by Grifols and CSL Behring, manufacturers of bleeding disorder medicines.  

The most common bleeding disorder in women is von Willebrand's, the charity said. Symptoms include frequent and heavy periods, bruising easily, frequent or heavy nosebleeds, bleeding heavily after surgery, prolonged bleeding after a dental procedure or abnormal bleeding after childbirth.

“There are tens of thousands of women in the UK currently living with a bleeding disorder without knowing. For many, this is because they think their symptoms are normal so they don't seek help,” said Liz Carroll, chief executive of the Haemophilia Society. 

“Our message is don't be embarrassed to talk about bleeding. The more we talk, the more informed women will be, and that can only help the thousands that are currently suffering in silence.”

Talking Red campaign events, including Paint it RED, and Red Knickers Night, will be staged across the UK to encourage people to be bold about bleeding. Participants can download posters and other materials from the campaign website

The pharma companies supporting the campaign are well-established providers of blood disorder treatments. 

Grifols develops plasma medicines, diagnostics systems, and hospital pharmacy products, while CSL Behring manufactures and markets a range of plasma-derived and recombinant therapies.

18th June 2014

From: Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...